137 related articles for article (PubMed ID: 35341178)
21. AKR1B1 Represses Glioma Cell Proliferation through p38 MAPK-Mediated Bcl-2/BAX/Caspase-3 Apoptotic Signaling Pathways.
Huang YK; Chang KC; Li CY; Lieu AS; Lin CL
Curr Issues Mol Biol; 2023 Apr; 45(4):3391-3405. PubMed ID: 37185746
[TBL] [Abstract][Full Text] [Related]
22. High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma.
Zhang F; Cai HB; Liu HZ; Gao S; Wang B; Hu YC; Cheng HW; Liu JX; Gao Y; Hong WM
Dis Markers; 2022; 2022():8133505. PubMed ID: 35493303
[TBL] [Abstract][Full Text] [Related]
23. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
24. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
25.
Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
[TBL] [Abstract][Full Text] [Related]
26. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
27.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
28. EPS15-AS1 Inhibits AKR1B1 Expression to Enhance Ferroptosis in Hepatocellular Carcinoma Cells.
Man Q; Zhang G; Chen X; Na SR; Bai S; Zhi H; Sun L; Pang H
J Cancer; 2024; 15(4):1030-1040. PubMed ID: 38230218
[TBL] [Abstract][Full Text] [Related]
29. PCGF1 is a prognostic biomarker and correlates with tumor immunity in gliomas.
Xie J; Qiao L; Deng G; Liang N; Xing L; Zhang J
Ann Transl Med; 2022 Feb; 10(4):227. PubMed ID: 35280367
[TBL] [Abstract][Full Text] [Related]
30. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
[TBL] [Abstract][Full Text] [Related]
31. Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.
Li G; Huang R; Fan W; Wang D; Wu F; Zeng F; Yu M; Zhai Y; Chang Y; Pan C; Jiang T; Yan W; Wang H; Zhang W
Front Immunol; 2021; 12():800928. PubMed ID: 34956239
[TBL] [Abstract][Full Text] [Related]
32. S100A6 is a potential diagnostic and prognostic biomarker for human glioma.
Hong B; Zhang H; Xiao Y; Shen L; Qian Y
Oncol Lett; 2023 Oct; 26(4):458. PubMed ID: 37736555
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Biomarker KIF18A and Its Correlations With Immune Infiltrates and Mitosis in Glioma.
Tao BY; Liu YY; Liu HY; Zhang ZH; Guan YQ; Wang H; Shi Y; Zhang J
Front Genet; 2022; 13():852049. PubMed ID: 35591854
[No Abstract] [Full Text] [Related]
34. LINC00978 regulates metabolic rewiring to promote the malignancy of glioblastoma through AKR1B1.
Meng M; Yang L; Zhou H; Cheng Q; Peng R; Wang Z; Liang X; Wen J; Nie J; Hu Z; Zhang L; Liu Z
Cancer Lett; 2023 Jul; 567():216277. PubMed ID: 37336288
[TBL] [Abstract][Full Text] [Related]
35. Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.
Familiari P; Lapolla P; Picotti V; Palmieri M; Pesce A; Carosi G; Relucenti M; Nottola S; Gianno F; Minasi S; Antonelli M; Frati A; Santoro A; D'Andrea G; Bruzzaniti P; LA Pira B
Anticancer Res; 2023 Jun; 43(6):2659-2670. PubMed ID: 37247932
[TBL] [Abstract][Full Text] [Related]
36. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
Lu VM; Alvi MA; Bydon M; Quinones-Hinojosa A; Chaichana KL
Clin Neurol Neurosurg; 2019 Jul; 182():32-36. PubMed ID: 31063969
[TBL] [Abstract][Full Text] [Related]
37. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
38. Aquaporin-4 as a New Potential Molecular Biomarker for Prognosis of Low-Grade Glioma: Comprehensive Analysis Based on Online Platforms.
Zhu J; Shi L; Su Y
World Neurosurg; 2023 Jul; 175():e713-e722. PubMed ID: 37037365
[TBL] [Abstract][Full Text] [Related]
39. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a prognostic gene expression signature for lower-grade glioma following surgery and adjuvant radiotherapy.
Qian DC; Marascio JA; Tobillo R; Lorenz JW; McCall NS; Neill SG; Hoang KB; Olson JJ; Eaton BR; Shu HG; Zhong J
Radiother Oncol; 2022 Oct; 175():93-100. PubMed ID: 35998839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
